Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Onyx™ Liquid Embolic IDE klinisk undersøgelse

8. oktober 2026 opdateret af: Medtronic Endovascular

PELE IDE klinisk undersøgelse, Perifer Onyx™ væskeembolisk sikkerhed og effektiviteten af ​​Onyx™ LES til embolisering af arteriel blødning i den perifere vaskulatur

The purpose of this study is to evaluate the safety and effectiveness of Onyx™ LES in the treatment of subjects with active arterial bleeding in the peripheral vasculature outside of the heart and brain.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

This is a pivotal, prospective, multi-center, non-randomized, single arm study. This study will enroll patients with active arterial bleeding in the peripheral vasculature confirmed by radiologic and/or endoscopic imaging and deemed suitable for embolization treatment by investigator. In this study, peripheral vasculature is defined as outside of the brain and heart.

Approximately 135 subjects will be consented to achieve 119 enrolled at up to 25 sites in the US.

This study will have two visits post-index procedure including hospital discharge visit and 30-day follow-up visit. Reintervention visits will be captured through 30 days post-index procedure.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

119

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

    • Arizona
      • Phoenix, Arizona, Forenede Stater, 85054
        • Rekruttering
        • Mayo Clinic
        • Kontakt:
        • Ledende efterforsker:
          • Sadeer Alzubaidi, MD
        • Kontakt:
          • Yahaira Parker
    • California
      • Irvine, California, Forenede Stater, 92627
      • Los Angeles, California, Forenede Stater, 90095
        • Rekruttering
        • University of California Los Angeles
        • Kontakt:
        • Ledende efterforsker:
          • Jessica Stewart, MD
      • Palo Alto, California, Forenede Stater, 94304
        • Rekruttering
        • Stanford Medical Center
        • Kontakt:
          • Andrew Picel, MD
        • Kontakt:
    • Colorado
      • Aurora, Colorado, Forenede Stater, 80045
        • Rekruttering
        • UCHealth University of Colorado Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Eduardo Bent Robinson, MD
    • Connecticut
    • Illinois
      • Chicago, Illinois, Forenede Stater, 60637
    • Iowa
      • Iowa City, Iowa, Forenede Stater, 52242
        • Rekruttering
        • University of Iowa Hospitals and Clinics
        • Ledende efterforsker:
          • Michael Hummel, MD
        • Kontakt:
    • Massachusetts
    • Nebraska
      • Omaha, Nebraska, Forenede Stater, 68124
        • Rekruttering
        • CHI Health Creighton University Medical Center-Bergan-Mercy
        • Kontakt:
        • Ledende efterforsker:
          • Patrick Harty
    • New Jersey
      • Newark, New Jersey, Forenede Stater, 07103
        • Rekruttering
        • Rutgers New Jersey Medical School
        • Ledende efterforsker:
          • Abhishek Kumar, MD
        • Kontakt:
    • New York
    • North Carolina
      • Chapel Hill, North Carolina, Forenede Stater, 27599
        • Rekruttering
        • University of North Carolina at Chapel Hill
        • Ledende efterforsker:
          • Nima Kokabi, MD
        • Kontakt:
    • Ohio
      • Cleveland, Ohio, Forenede Stater, 44106
        • Rekruttering
        • University Hospitals Cleveland Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Salim Abboud, MD
      • Columbus, Ohio, Forenede Stater, 43210
        • Rekruttering
        • The Ohio State University
        • Kontakt:
          • Mina Makary, MD
        • Kontakt:
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Forenede Stater, 15237
        • Rekruttering
        • University of Pittsburgh Medical Center
        • Ledende efterforsker:
          • Paula Novelli, MD
        • Kontakt:
    • Tennessee
      • Nashville, Tennessee, Forenede Stater, 37212
        • Rekruttering
        • Vanderbilt University Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Anthony Borgmann, MD
    • Texas
      • Dallas, Texas, Forenede Stater, 75235
        • Rekruttering
        • Univ Of Texas Southwestern
        • Ledende efterforsker:
          • Sanjeeva Kalva, MD
        • Kontakt:
      • Houston, Texas, Forenede Stater, 77030

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

22 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Patient is ≥ 22 years old.

  2. Active arterial bleeding in the peripheral vasculature confirmed by radiologic and/or endoscopic imaging and deemed suitable for embolization treatment by the investigator.

    In this study, peripheral vasculature is defined as outside the brain and heart.

  3. Patient or legally authorized representative (LAR) is able to provide written consent to participate in the study.

  4. Life expectancy of >30 days, in the opinion of the investigator at the time of enrollment.

  5. Target treatment area is free from prior embolization treatment.

Exclusion Criteria:

  1. Pregnant or breastfeeding.
  2. Symptoms of active infection.
  3. Patient is known to be participating in the study of an investigational drug, biologic, or device.
  4. Contrast allergy or other contraindication to angiography, CT, or catheterization, including contrast sensitivity that cannot be adequately treated prior to index procedure.
  5. Known allergy to components of Onyx™.
  6. Target vasculature unsuitable for the delivery of Onyx™ based upon physician assessment.
  7. More than 4 target lesions will require embolization, in the investigator's opinion after imaging-based assessment.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Treatment with Onyx LES

Device; embolization with liquid embolic

The proposed indication for Onyx™ LES is: Onyx™ LES is indicated for the embolization of arterial hemorrhage in the peripheral vasculature.

Andre navne:
  • Embolisering

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Freedom from Arterial Hemorrhage
Tidsramme: Through 30 days post-index procedure

Freedom from arterial hemorrhage in all target location(s) after treatment with Onyx™ LES at the index procedure without re-embolization or any other intervention at the target location(s) due to persistent or recurrent hemorrhage through 30 days. Freedom from arterial hemorrhage where an arterial hemorrhage event is defined as a type 3 or greater BARC bleeding criteria as assessed by the Clinical Events Committee (CEC) through 30 days.

Through 30 days post-index procedure
Freedom from System-related Major Adverse Events (MAE)
Tidsramme: Through 30 days post-index procedure

The primary safety endpoint is defined as freedom from system-related Major Adverse Events (MAE) through 30 days after the point of enrollment as assessed by the CEC.

Through 30 days post-index procedure

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Procedural Success
Tidsramme: At the completion of the index procedure

successful delivery and deployment of Onyx™ to the target location without non-target embolization or Onyx™ cast migration and the successful removal of the delivery system at the completion of the index procedure.

At the completion of the index procedure
Technical Success
Tidsramme: At the completion of the index procedure

Technical Success is defined as absence of angiographic signs of bleeding after Onyx ™ embolization at each target location based on core lab assessment.

At the completion of the index procedure
Reintervention
Tidsramme: Through 30 days post-index procedure

Reintervention is defined as the number of additional procedures needed to treat the target location(s) embolized with Onyx™ through 30 days following the index procedure.

Through 30 days post-index procedure
Transfusions
Tidsramme: Through 30 days post-index procedure

Transfusions defined as the number of blood transfusions required post-index procedure through 30 days will use blood transfusions starting after the removal of the delivery system. The number of blood units used for each transfusion will also be collected.

Through 30 days post-index procedure

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Ancillary Endpoint
Tidsramme: Through index procedure

Duration of the index procedure

Through index procedure
Ancillary Endpoint
Tidsramme: Through 30 days post-index procedure

Length of hospitalization, post-index procedure

Through 30 days post-index procedure
Ancillary Endpoint
Tidsramme: Through 30 days post-index procedure

Tabulate adjunctive use of other types of embolic agents to treat target locations at index procedure and reinterventions

Through 30 days post-index procedure

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Ledende efterforsker: Osman Ahmed, MD, University of Chicago

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

9. maj 2025

Primær færdiggørelse (Anslået)

1. april 2027

Studieafslutning (Anslået)

1. maj 2027

Datoer for studieregistrering

Først indsendt

11. december 2024

Først indsendt, der opfyldte QC-kriterier

18. december 2024

Først opslået (Faktiske)

19. december 2024

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

13. oktober 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

8. oktober 2026

Sidst verificeret

1. oktober 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • MDT21044

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ja

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .